Clin Oncol | Volume 2, Issue 1 | Research Article | Open Access

Elastofibroma dorsi: An Association with Hematological Malignancies

Mohamed Elshikh1*#, Bilal Mujtaba2#, William Murphy2, Peter Wei3, Jesse Rayan4, Ahmed Elsayes2, Jia Sun5 and Naveen Garg2

1Department of Internal Medicine, Medstar Union Memorial Hospital, Baltimore, MD, USA
2Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, USA
3Department of Diagnostic and Interventional Radiology, The University of Texas Health Science Center at Houston, USA
4Department of Diagnostic Radiology, Baylor College of Medicine, Houston, USA
5Department of Biostatistics, The University of Texas MD Anderson Cancer Center, USA
#These authors contributed equally to this manuscript

*Correspondance to: Mohamed Elshikh 

Fulltext PDF

Abstract

Background: Elastofibroma dorsi (ED), a benign soft tissue tumor, has multiple chromosomal mutations in 3q21, 1p32, 6q25, Xq and 19q13. Most of these mutations are also present in multiple hematological malignancies. However, the clinical prevalence of ED in patients with hematological or solid malignancies has not yet been reported. The purpose of this study was to investigate the association between ED and other malignancies.Methods: In this case-control study, we identified 52 ED patients (cases) and randomly selected 150 non–ED-patients (controls) who underwent Computed Tomography (CT) at our institution between 1973 and 2015. Owing to the various malignancy subtypes, limited sample sizes, and predominance of Diffuse Large B-cell Lymphoma (DLBCL) in these cohorts, Patients were pooled into 1 of 3 categories: DLBCL, no cancer, and other cancers. The primary endpoints were the odds ratios (ORs) of no cancer and other cancers using DLBCL as a reference. The second endpoints were the ORs of affected systems using hematological malignancies as a reference.Results: The mean age of the ED patients was significantly higher than that of the control patients (P = 0.0003). Compared with control patients, ED patients had a higher risk of having DLBCL than no cancer (P = 0.029) or other cancers (P = 0.001) and had a higher probability of having hematological malignancies than other systems’ cancers (P = 0.002).Conclusions: Compared with patients without ED, patients with ED have a higher risk of developing hematological malignancies, especially DLBCL. This association is likely secondary to the mutations shared by ED and hematological malignancies.

Citation:

Elshikh M, Mujtaba B, Murphy W, Wei P, Rayan J, Elsayes A, et al. Elastofibroma dorsi: An Association with Hematological Malignancies. Clin Oncol. 2017; 2: 1338.

Subscribe to Our Newsletter